BioCryst Pharmaceuticals, Inc.
About BioCryst Pharmaceuticals, Inc.BioCryst Pharmaceuticals, Inc. Founded in 1986, BioCryst Pharmaceuticals, Inc. is a bio-pharmaceutical company focused on the development of pharmaceuticals. BioCryst designs, optimizes and develops novel small-molecule drugs that block key enzymes involved in infectious and rare diseases. BioCryst's core development programs include BCX4161 and two 2nd generation oral inhibitors of plasma kallikrien for hereditary angioedema; peramivir, a viral neuraminidase inhibitor for the treatment of influenza and BCX4430, a broad spectrum antiviral for hemorrhagic fevers. For more information, visit our web site at www.biocryst.com Chemistry Department Openings BioCryst Pharmaceuticals, Inc. is currently seeking highly motivated synthetic organic chemist for a Ph.D. Medicinal Chemistry positions available in Birmingham, Alabama. Duties include participation in drug design, synthesis, purification, and characterization of novel small organic molecules. Interdisciplinary teams of synthetic organic chemists work with crystallography/molecular modeling to produce novel small molecule new chemical entities as pharmaceutical candidates. The Chemistry Department is responsible for all chemistry aspects of small molecule drug substance development within BioCryst. Current openings include: Synthetic Organic Chemist - The successful candidate will have a distinguished academic record, demonstrated laboratory skills, a suitable publication record, leadership and problem-solving skills, as well as a demonstrated ability to work in an interdisciplinary team environment. The candidate must have a Ph.D. degree in Chemistry. Please send your resume, to: Pravin Kotian, 2190 Parkway Lake Drive, Birmingham, AL 35244, email firstname.lastname@example.org fax 205-444-4640 BioCryst provides a comprehensive compensation and benefits package and we are an Equal Opportunity Employer, M/F/D/V.
1 job with BioCryst Pharmaceuticals, Inc.
We are currently seeking a Chemistry Patent Agent for our discovery and CMC group.